Search for Clinical Trial Results
Adult T-cell Leukemia/lymphoma - 310 Studies Found
Status | Study |
Completed |
Study Name: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Condition: T-ALL, T-NHL (Lymphoblastic) Date: 2008-05-16 Interventions: Drug: Nelarabine 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5 |
Completed |
Study Name: A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Condition:
Date: 2010-07-22 Interventions: Drug: Lenalidomide Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily o |
Completed |
Study Name: A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Condition:
Date: 2005-09-01 Interventions:
|
Completed |
Study Name: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 Condition: Adult T-cell Leukemia-Lymphoma Date: 2010-07-30 Interventions:
|
Terminated |
Study Name: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Condition:
Date: 2008-06-13 Interventions: Drug: Panobinostat (LBH589) 20mg/day p.o. on three times-a- week |
Recruiting |
Study Name: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Condition:
|
Completed |
Study Name: Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 Condition: Human T-Lymphoma Virus Type I Date: 2006-06-19 |
Completed |
Study Name: Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL Condition:
|
Terminated |
Study Name: Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Condition:
Date: 2009-02-28 Interventions:
|
Completed |
Study Name: Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Condition: Acute T-Cell Leukemia-Lymphoma Date: 2003-05-20 Interventions: Biological: Alemtuzumab Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 follo |